Skip to Content

Farydak (panobinostat) Disease Interactions

There are 5 disease interactions with Farydak (panobinostat):


Panobinostat (Includes Farydak) ↔ Cardiac Toxicity

Severe Potential Hazard, Moderate plausibility

Applies to: Arrhythmias, Ischemic Heart Disease, Electrolyte Abnormalities

Severe and fatal cardiac ischemic events, as well as severe arrhythmias, and electrocardiogram (ECG) changes have occurred in patients receiving panobinostat. Panobinostat may prolong cardiac ventricular repolarization (QT interval). Do not initiate treatment with panobinostat in patients with a QTcF >450 msec or clinically significant baseline ST-segment or T-wave abnormalities. If during treatment, the QTcF increases to >=480 msec, interrupt treatment. Arrhythmias may be exacerbated by electrolyte abnormalities. It is recommended to obtain ECG at baseline and periodically during treatment as clinically indicated. Monitor patient hydration status and electrolyte blood levels, including potassium, magnesium and phosphate, at baseline and frequently as clinically indicated during therapy and correct to prevent dehydration and electrolyte disturbances. If QT prolongation does not resolve, permanently discontinue treatment with panobinostat.


Panobinostat (Includes Farydak) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Hepatic impairment can increase panobinostat exposure. It is recommended to reduce the starting dose of panobinostat in patients with mild or moderate hepatic impairment. Avoid the use of panobinostat in patients with severe hepatic impairment. Liver function should be monitored prior to treatment and regularly during treatment. If abnormal liver function tests are observed dose adjustments might be considered and the patient should be followed until values return to normal or to pretreatment levels.


Panobinostat (Includes Farydak) ↔ Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Localized and systemic infections, including pneumonia, bacterial infections, invasive fungal infections, and viral infections have been reported in patients taking panobinostat. It is recommended to monitor patients for signs and symptoms of infections during treatment; if a diagnosis of infection is made, institute appropriate anti-infective treatment promptly and consider interruption or discontinuation of therapy. Care should be exercised when prescribing this agent to patients at risk.


Panobinostat (Includes Farydak) ↔ Myelosuppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Anemia, Bone Marrow Depression/Low Blood Counts

Panobinostat causes myelosuppression. Cases of severe thrombocytopenia, neutropenia and anemia have been reported with the use of panobinostat. It is recommended to obtain a baseline CBC and monitor the CBC frequently as clinically indicated. Dose modifications are recommended for myelosuppression.


Panobinostat (Includes Farydak) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Mild renal impairment to severe renal impairment did not impact the plasma exposure of panobinostat. The use of panobinostat has not been studied in patients with end stage renal disease or patients on dialysis. Care should be exercised when using panobinostat in these patients as the dialyzability of panobinostat is unknown.

Farydak (panobinostat) drug Interactions

There are 830 drug interactions with Farydak (panobinostat)

Farydak (panobinostat) alcohol/food Interactions

There is 1 alcohol/food interaction with Farydak (panobinostat)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.